Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTx408
- Development stage
- Unknown
- Lead developer
- Primal Therapies
- Modality
- Small Molecules
01
Overview
**PTx408** is a Primal Therapies pipeline asset associated with the company's SMMRT microbial-metabolism-regulation platform. Primal Therapies describes its platform as using patented small-molecule agents, including prebiotics, postbiotics, and antimicrobials, to selectively modulate microbial metabolism, disrupt undesirable biofilms, and support microbiome control. The company has listed PTx408 among its pipeline assets, but has not publicly disclosed its exact active ingredients, molecular targets, therapeutic indication, dosage form, route of administration, or development stage. ([primaltherapies.com](https://primaltherapies.com/))
Beyond the preview
Go deeper on PTx408.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTx408.